(Q36579633)

English

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

scientific article published on 10 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression (English)

1 reference

Europe PubMed Central

15 August 2017

1 reference

based on heuristic

inferred from title

9

object named as

Marc Ladanyi

1 reference

Europe PubMed Central

15 August 2017

4

object named as

William Pao

1 reference

Europe PubMed Central

15 August 2017

8

object named as

Mark G Kris

1 reference

Europe PubMed Central

15 August 2017

Dhananjay A Chitale

2

object named as

Dhananjay Chitale

1 reference

Europe PubMed Central

15 August 2017

Valerie W Rusch

7

object named as

Valerie Rusch

1 reference

Europe PubMed Central

15 August 2017

Gregory J Riely

3

object named as

Gregory J Riely

1 reference

Europe PubMed Central

15 August 2017

Maureen F Zakowski

6

object named as

Maureen F Zakowski

1 reference

Europe PubMed Central

15 August 2017

author name string

Allan R Li

1

1 reference

Europe PubMed Central

15 August 2017

Vincent A Miller

5

1 reference

Europe PubMed Central

15 August 2017

publication date

10 April 2008

1 reference

Europe PubMed Central

15 August 2017

The Journal of Molecular Diagnostics

1 reference

Europe PubMed Central

15 August 2017

10

1 reference

Europe PubMed Central

15 August 2017

242-248

1 reference

Europe PubMed Central

15 August 2017

3

1 reference

Europe PubMed Central

15 August 2017

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

Epidermal growth factor receptor mutation testing in the care of lung cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

9 September 2017

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

20 September 2018

EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

20 September 2018

Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

20 September 2018

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

20 September 2018

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

20 September 2018

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

20 September 2018

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

20 September 2018

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2329789

20 September 2018

Immunocytochemical markers in stage I lung cancer: relevance to prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18403609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

1 reference

https://pubmed.ncbi.nlm.nih.gov/18403609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method

1 reference

https://pubmed.ncbi.nlm.nih.gov/18403609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18403609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2353/JMOLDX.2008.070178

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36579633&oldid=1738896105"